Abstract: A NLRP3-inhibitory compound 7 (NIC7) and a potent derivative NIC7w are disclosed. NLRP3-inhibitory compound 7 (NIC7) and a potent derivative NIC7w are a novel small-molecule inhibitor for inhibiting NLRP3 inflammasomes are identified. These compounds inhibit main elements of the NLRP3 signaling pathway, primarily IL-1? and caspase 1, and improve cognitive behaviors of mice in Alzheimer disease mouse models. Compositions of NIC7 and NIC7w are suitable as a therapeutic agent in treating, preventing, or improving the conditions of Alzheimer's disease.

Abstract: An antenna module includes a first antenna unit including at least one first patch antenna pattern, at least one first feed via, and at least one first dielectric layer, a second antenna unit including at least one second patch antenna pattern, at least one second feed via, and at least one second dielectric layer, a first connection portion, a first rigid substrate electrically connecting the first connection portion to the first antenna unit and having a first surface on which the first antenna unit is disposed, a base connection portion, a flexible substrate having a first surface on which the first connection portion is disposed and a second surface on which the base connection portion is disposed, and an IC electrically connected to the flexible substrate through the second surface of the flexible substrate or the first rigid substrate.

Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.

Abstract: A substrate processing apparatus includes a photoresist coater applying a photoresist film on a substrate, a humidifier increasing an amount of moisture in an ambient to which the photoresist film on the substrate is exposed, and an exposer irradiating the photoresist film exposed to the ambient having the increased amount of moisture with light. The humidifier is disposed between the photoresist coater and the exposer.

Abstract: The present invention relates to a heteroaryl derivative compound and a use thereof. Since the heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, the heteroaryl derivative can be usefully used as a therapeutic agent for EGFR-associated diseases.

Abstract: The present invention relates to a recombinant microorganism producing quinolinic acid, more particularly, a microorganism producing quinolinic acid and having attenuated activity or eliminated activity of a protein having a sequence of SEQ ID NO: 1 and a method of producing quinolinic acid by using the recombinant microorganism.

Abstract: The present invention relates to a polypeptide which is resistant to feedback inhibition by methionine and has an activity of homoserine O-succinyltransferase, a microorganism for producing O-succinylhomoserine which expresses the polypeptide, and a method for producing O-succinylhomoserine using the same.

Abstract: The present invention relates to a feed additive composition having a high content of L-methionine, and an animal feed composition comprising the feed additive composition. More specifically, the present invention relates to a feed additive composition comprising 60 to 99.9 wt % of L-methionine together with L-phenylalanine and L-tyrosine, and to an animal feed composition comprising the feed additive composition.

Abstract: The present invention relates to a recombinant microorganism producing quinolinic acid, more particularly, a microorganism producing quinolinic acid and having attenuated activity or eliminated activity of a protein having a sequence of SEQ ID NO: 1 and a method of producing quinolinic acid by using the recombinant microorganism.

Abstract: The present invention relates to a method for enhancing the solubility of methionine. More particularly, the present invention relates to a method for increasing the solubility of methionine, in which mineral and sulfuric acid are added at an appropriate ratio to enhance the methionine solubility, thereby overcoming the problem of low solubility of methionine in water.

Abstract: The present invention relates to a quinolinic acid-producing recombinant microorganism expressing a fusion protein of L-aspartate oxidase and quinolinate synthase linked via a linker, and a method for producing quinolinic acid using the same.

Abstract: The present invention relates to a polypeptide which is resistant to feedback inhibition by methionine and has an activity of homoserine O-succinyltransferase, a microorganism for producing O-succinylhomoserine which expresses the polypeptide, and a method for producing O-succinylhomoserine using the same.

Abstract: A method for the preparation of nicotinic acid, which includes the step of obtaining a culture solution containing quinolinic acid by incubating a microorganism having an ability to produce quinolinic acid, and the step of adding an acid to the culture solution and conducting a decarboxylation reaction.

Abstract: To produce quinolinate effectively, a L-aspartate oxidase variant that the feedback regulation by nicotinic acid or NAD is released, and a microorganism including the L-aspartate oxidase variant are provided. Quinolinate may be effectively produced by culturing of the microorganism including the L-aspartate oxidase variant.

Abstract: The present invention relates to a polypeptide that is modified to have homoserine O-acetyltransferase activity, and in particular, the present invention provides a modified polypeptide having homoserine O-acetyltransferase activity, in which the amino acid at position 111 of a polypeptide having homoserine succinyltransferase activity is substituted with other amino acid.

Abstract: The present invention relates to a novel protein having O-acetylhomoserine sulfhydrylase activity, a mutant protein thereof, a polynucleotide encoding the same, a recombinant vector comprising the polynucleotide, a microorganism transformed with the recombinant vector, and a method for producing methionine or acetic acid using the protein. The production method of the present invention has the advantage of producing L-methionine and acetic acid cost-effectively through having higher conversion rate and reduced reaction time compared to the existing methods, and it can minimize the amount of enzyme homogenate added when using the mutant protein, thereby easily producing L-methionine and acetic acid at high yield.

Abstract: The present invention relates to a method for increasing L-methionine productivity and organic acid productivity. More particularly, the present invention relates to a method which involves adding a mixture containing methyl mercaptan and dimethyl sulfide at a appropriate ratio to O-acetyl homoserine or O-succinyl homoserine and to an enzyme having an activity of converting methionine precursor into L-methionine, so as to perform an enzyme reaction, to thereby improve the conversion rate of L-methionine and organic acid from the L-methionine precursor, and thus increasing L-methionine yield as compared to conventional method.

Abstract: The present invention relates to a microorganism producing L-methionine precursor, O-acetylhomoserine, and a method of producing L-methionine precursor using the microorganism.

Abstract: The present invention relates to a quinolinic acid-producing recombinant microorganism expressing a fusion protein of L-aspartate oxidase and quinolinate synthase linked via a linker, and a method for producing quinolinic acid using the same.

Abstract: To produce quinolinate effectively, a L-aspartate oxidase variant that the feedback regulation by nicotinic acid or NAD is released, and a microorganism including the L-aspartate oxidase variant are provided. Quinolinate may be effectively produced by culturing of the microorganism including the L-aspartate oxidase variant.